Preimplantation Genetic Testing Market Expected To Touch New Height Of $107.3 Million By 2024

Grand view research, inc - Sunday, August 8, 2021.
Submitted by Sara White.

The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

Malaysia preimplantation genetic testing market

To request a sample copy or view summary of this report, click the link below:

Further key findings from the report suggest:

  • Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
  • Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
  • Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
  • Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
  • Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
  • Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
  • Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
  • Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
  • Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application, and region:

Preimplantation Genetic Testing (PGT) PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)

  • Preimplantation Genetic Diagnosis (PGD)
  • Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Testing (PGT) (PGS/PGD) Type Outlook (Revenue, USD Million, 2014 - 2024)

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
    • Fresh Embryo (Own Eggs)
    • Frozen Embryo (Own Eggs)
    • Fresh Embryo (Donor Eggs)
    • Frozen Embryo (Donor Eggs)
  • Aneuploidy Screening
  • HLA Typing
  • Other PGT Types

Preimplantation Genetic Testing (PGT) (PGS/PGD) Application Outlook (Revenue, USD Million, 2014 - 2024)

  • Embryo HLA typing for stem cell therapy
  • IVF Prognosis
  • Late Onset Genetic Disorders
  • Inherited Genetic Disease
  • Others

Preimplantation Genetic Testing (PGT) (PGS/PGD) Regional Outlook (Revenue, USD Million, 2014 - 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Spain
    • Belgium
    • Czech Republic
    • Poland
    • Sweden
    • Finland
    • Norway
    • Netherlands
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • Singapore
    • Malaysia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Chile
  • Middle East and Africa (MEA)
    • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

About Grand view research, inc


Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit


More about Grand view research, inc